Website: aragen.com   |   LinkedIn: linkedin.com/company/aragen-life-sciences

From DNA to IND, Without the Guesswork

How Aragen Biosciences gives biotech and pharma a faster, more predictable path through biologics development

At a glance

  • Company: Aragen Biosciences (aragen.com)
  • S. biologics campus: Morgan Hill, California, at the south end of Silicon Valley, serving Bay Area biotech since 1993
  • Global network: Part of Aragen, a global contract research, development, and manufacturing organization (CRDMO) with GMP biologics manufacturing in Bengaluru, India
  • Focus: Cell line development, process and analytical development, preclinical research, and GMP manufacturing of biologics
  • Working with PSG on: Sales performance improvement

A Silicon Valley lab with a global reach

For more than three decades, Aragen’s Morgan Hill site has been a trusted lab partner for biotech and pharma, starting as Sierra BioSource and growing into the U.S. hub of a global CRDMO.

Today, Aragen runs a dual-hub model for biologics. Discovery, cell line development, and early process work happen in Morgan Hill, close to U.S. innovators. When a program is ready for GMP production, it moves to Aragen’s $40 million commercial biologics facility in Bengaluru, built for intensified processing and scale-up. Sponsors get one partner and one workflow from the first clone to clinical supply.

CHOMax: a clear path to the clinic

In January 2026, Aragen launched CHOMax™, an integrated platform that moves standard IgG antibody programs from DNA to IND-enabling clinical supply in about 10 months.

  • Proven at scale: refined across 200+ CHO programs
  • High productivity: titers of 8 g/L at the clonal stage for many standard IgGs, and up to 27 g/L after process optimization (molecule-dependent)
  • Royalty-free: sponsors own their cell line, with no platform royalties or back-end fees
  • Parallel CMC: cell line, process, analytical development, and GMP manufacturing run under one quality system, with pre-agreed decision points that cut rework and timeline risk
  • Built for complex formats: experience with bispecifics, antibody fragments, Fc-fusion proteins, biosimilars, and even canine and feline antibodies

Results that speak for themselves

Aragen’s track record includes more than 200 cell line development programs and four commercial products made with Aragen cell lines.

A recent example: Aragen developed the cell line and initial process for Renaissance Pharma’s anti-GD2 antibody, Daretabart, in Morgan Hill, then tech-transferred it to Bengaluru in nine months. The transfer delivered a several-fold titer increase and right-first-time execution at 2,000-liter GMP scale. The program has since received FDA Fast Track Designation for high-risk neuroblastoma.

More than manufacturing

Aragen supports programs well before GMP, too:

  • Discovery and protein sciences: protein expression and purification, molecular and cell biology, and immunology
  • Preclinical research: AAALAC-accredited in vivo services, including oncology and immunology efficacy models
  • Analytical characterization: method development, qualification, and QC support